May 13, 2020 / 9:53 PM / 21 days ago

BRIEF-Merck Says Data Show Keytruda Monotherapy Significantly Reduced Risk Of Disease Progression Or Death By 35% Compared With BV

May 13 (Reuters) - Merck & Co Inc:

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SUPERIOR TO BRENTUXIMAB VEDOTIN (BV), A STANDARD OF CARE, IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) IN HEAD-TO-HEAD PHASE 3 TRIAL

* MERCK & CO INC - DATA SHOW KEYTRUDA MONOTHERAPY SIGNIFICANTLY REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 35% COMPARED WITH BV

* MERCK - KEYTRUDA DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN PHASE 3 CHL STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below